ReviewRheumatology and therapy2017
Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.
Review in Rheumatology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.Annals of the rheumatic diseases · 2021Guideline
- Associations of Atherogenic Lipid Ratios and Visceral Adiposity Indices with Cardiovascular Risk Scores in Rheumatoid Arthritis.Archives of rheumatology · 2026Article
- Local ice cryotherapy reduced vascular inflammation in large artery from rats with arthritis.Scientific reports · 2026Article
- Cardiovascular Risk Management In Patients With Rheumatoid Arthritis: A Systematic Review.Cureus · 2024Review
- Remotely Supervised Weight Loss and Exercise Training to Improve Rheumatoid Arthritis Cardiovascular Risk: Rationale and Design of the Supervised Weight Loss Plus Exercise Training-Rheumatoid Arthritis Trial.ACR open rheumatology · 2023Review
- Uncovering mechanisms of brain inflammation in Alzheimer's disease with APOE4: Application of single cell-type lipidomics.Annals of the New York Academy of Sciences · 2022Review
- Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes.Therapeutic advances in musculoskeletal disease · 2022Review
- Accelerated atherosclerosis in premenopausal women with rheumatoid arthritis - 15-year follow-up.Bosnian journal of basic medical sciences · 2021Article
- Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.Advances in rheumatology (London, England) · 2021Observational
- The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review.Journal of clinical medicine · 2021Review
- Clinicopathologic features of rheumatoid nodules: a retrospective analysis.Clinical rheumatology · 2019Article
- The Microbial Metabolite Trimethylamine N-Oxide Links Vascular Dysfunctions and the Autoimmune Disease Rheumatoid Arthritis.Nutrients · 2019Review
- [Serum lipid profile in children with different subtypes of juvenile idiopathic arthritis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2019Article
- Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due to the lack of specifically designed randomized clinical trials, it is still unclear which tools to use to perform CV risk assessment, how to interpret the results and which interventions are appropriate in RA patients both to prevent and to manage CVD. Based on the available evidence, we propose a practical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.